Buscopan and Oesophageal Achalasia

Wright, J. T.

doi:10.1259/0007-1285-34-398-113

Cited by 14 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a ganglion-blocking agent, having no central action (unlike scopolamine), and causes only minor atropine-like side-reactions unless doses of over 40 mg are employed (WRIGHT 1961). The higher doses as favoured by some authors (KRIESSMAN, NOVAK & PROBST) lead to a significant incidence of side-effects such as dryness of the mucous membranes, mydriasis, palpitations, nausea and headaches.…”

Section: Discussionmentioning

confidence: 99%

Hyoscine-N-Butylbromide (Buscopan) as a Duodenal Relaxant in Tubeless Duodenography

Ayre-Smith¹

1976

Acta Radiologica. Diagnosis

View full text Add to dashboard Cite

The efficacy of Buscopan in tubeless duodenography was tested in 48 patients using different routes of administration. The drug led to successful results in 77 to 85 per cent of patients in the dosage used (40 mg), the intravenous route proving the most efficient. The drug is considered superior to Probanthine and glucagon (Glucagon-Lilly) in view of its safety, low incidence of side-effects and efficacy. Follow-through examinations of the small bowel at 1 hour are possible in 33 per cent of patients, although 40 per cent have mild residual abnormalities only.

show abstract

Section: Discussionmentioning

confidence: 99%

Hyoscine-N-Butylbromide (Buscopan) as a Duodenal Relaxant in Tubeless Duodenography

Ayre-Smith¹

1976

Acta Radiologica. Diagnosis

View full text Add to dashboard Cite

show abstract

“…In an attempt to achieve this, a great variety of compounds have been tried. However, most acute 10 –24 and chronic 25 –33 studies to date were not controlled and usually included a small number of patients; only a few single‐ or double‐blind, placebo‐controlled investigations are available 34 –38 (Tables 1–3).…”

Section: Methodsmentioning

confidence: 99%

Review article: pharmacological options in achalasia

Bassotti

Annese

1999

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Achalasia is a common primary oesophageal motor disorder. Treatment has been based traditionally on a surgical approach; however, there is new evidence that some medical strategies may be of benefit. The purpose of the present article was to review the current medical management of achalasia. A Medline search identified original articles and reviews published in the English‐language literature between 1966 and 1998. This search has revealed that the pharmacological treatment of achalasia is limited to some subgroups of patients (for example, early stages of the disease and elderly patients), and that nitrates, nifedipine, and botulinum toxin are the best studied and most effective compounds.

show abstract

“…Current oral drugs used to treat AC include nitrates, calcium channel blockers, phosphodiesterase inhibitors, and some others (butylscopolamine, nifedipine, verapamil, carbutoerol, terbutaline, aminophylline, nitroglycerin, vasoactiveintestinalpeptide, cimetropium, loperamide, isosorbide, and sildenafil). [63][64][65][66][67][68][69][70][71][72][73][74][75] These drugs transiently relax LES smooth muscle and facilitate esophageal emptying.…”

Section: Quality Of Evidence: 2+ Classification Of Recommendation: Amentioning

confidence: 99%

Management of achalasia cardia: Expert consensus statements

Ramchandani

Reddy

Nabi

et al. 2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

Achalasia cardia (AC) is a frequently encountered motility disorder of the esophagus resulting from an irreversible degeneration of neurons. Treatment modalities are palliative in nature, and there is no curative treatment available for AC as of now. Significant advancements have been made in the management of AC over last decade. The introduction of high resolution manometry and per-oral endoscopic myotomy (POEM) has strengthened the diagnostic and therapeutic armamentarium of AC. High resolution manometry allows for the characterization of the type of achalasia, which in turn has important therapeutic implications. The endoscopic management of AC has been reinforced with the introduction of POEM that has been found to be highly effective and safe in palliating the symptoms in short-term to mid-term follow-up studies. POEM is less invasive than Heller's myotomy and provides the endoscopist with the opportunity of adjusting the length and orientation of esophageal myotomy according to the type of AC. The management of achalasia needs to be tailored for each patient, and the role of pneumatic balloon dilatation, POEM, or Heller's myotomy needs to be revisited. In this review, we discuss the important aspects of diagnosis as well as management of AC. The statements presented in the manuscript reflect the cumulative efforts of an expert consensus group.

show abstract

Buscopan and Oesophageal Achalasia

Cited by 14 publications

References 5 publications

Hyoscine-N-Butylbromide (Buscopan) as a Duodenal Relaxant in Tubeless Duodenography

Hyoscine-N-Butylbromide (Buscopan) as a Duodenal Relaxant in Tubeless Duodenography

Review article: pharmacological options in achalasia

Management of achalasia cardia: Expert consensus statements

Contact Info

Product

Resources

About